Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ TGE Announces Strong Pipeline of New Movies, Enjoying a Strategic Partnership with Alibaba Pictures (PR Newswire) +++ GENERATION ESSENTIALS Aktie +11,50%

GlaxoSmithkline Capital Inc. DL-Notes 2018(18/28) Anleihe

 >Anleihen REALTIME KURS 
99.564 EUR    (Tradegate)
Ask: 99.639 EUR / 100000 Stück
Bid: 99.489 EUR / 100000 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von Tradegate!
>Anleihen Kennzahlen
Name:  GlaxoSmithkline Capital Inc. DL-Notes 2018(18/28)
Typ:  Anleihe
Zuordnung:  GSK, GSK ADR
Kategorie:  Unternehmensanleihe
ISIN:  US377372AN70
Wkn:  A190V5
Symbol/ Ticker:  -
Kürzel:  -
>Anleihen Performance
1 Woche: -0,1%
1 Monat: +0,3%
3 Monate: +0,8%
6 Monate: +1,8%
1 Jahr: +1,0%
laufendes Jahr: +2,3%
>Anleihen Peer Group

Es sind 2 Wertpapiere bekannt.
 
16.08.25 - 16:15
 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK (PR Newswire)
 
NEW YORK, Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns......
13.08.25 - 23:42
 XFRA: DIVIDEND/INTEREST INFORMATION - 14.08.2025 - GB00BN7SWP63 (XETRA)
 
Das Instrument GS71 GB00BN7SWP63 GSK PLC LS-,3125 EQUITY wird ex Dividende/Zinsen gehandelt am 14.08.2025 The instrument GS71 GB00BN7SWP63 GSK PLC LS-,3125 EQUITY has its ex-dividend/interest day on 14.08.2025...
13.08.25 - 17:51
 Mersana targets reporting initial Emi-Le expansion data in H2 2025 while achieving $15M GSK milestone (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.08.25 - 22:06
 Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
 
YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1 Pivotal Phase 3 CYPRESS study enrollment on track to complete by late summer Completed sale of TRELEGY ELLIPTA royalty interest to GSK for $225 million TRELEGY year-to-date sales on......
12.08.25 - 15:18
 GSK Aktie: Bewertung weiterhin im Keller (Aktiencheck)
 
Wien (www.aktiencheck.de) - GSK-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), rät die Aktie von GSK plc (ISIN: GB00BN7SWP63, WKN: A3DMB5, Ticker-Symbol: GS71, London Stock Exchange-Symbol: GSK, NASDAQ OTC-Symbol: GLAXF) nach wie vor zu kaufen. [mehr]...
12.08.25 - 07:48
 Down 16% from its year high, GSK′s share price looks 68% undervalued to me now despite strong H1 results! (Fool)
 
GSK's share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely underpriced compared to its fair value. The post Down 16% from its year high, GSK's share price looks 68% undervalued to me now despite strong H1 results! appeared first on The Motley Fool UK....
11.08.25 - 23:33
 IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight (PR Newswire)
 
The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a strong pipeline of clinical trials, and growing regulatory approvals. Leading companies such as GlaxoSmithKline, Mirum Pharmaceuticals,......
11.08.25 - 16:01
 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK (PR Newswire)
 
NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns......
11.08.25 - 13:42
 GSK bid to expand Blujepa label for gonorrhea granted FDA priority review (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
11.08.25 - 10:01
 GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
11.08.25 - 10:00
 GSK gepotidacin edges closer to landmark approval for gonorrhoea (ShareCast)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
11.08.25 - 09:12
 GSK: Gepotidacin Accepted For FDA Priority Review For Uncomplicated Urogenital Gonorrhoea (AFX)
 
LONDON (dpa-AFX) - British drug major GSK plc (GSK, GSK.L) announced Monday that the US Food and Drug Administration has accepted for priority review a supplemental New Drug Application for gepoti......
11.08.25 - 08:36
 FDA prüft GSK-Mittel Gepotidacin vorrangig gegen Gonorrhoe (Dow Jones)
 
Von Cristina Gallardo DOW JONES--Die US-Arzneimittelbehörde FDA will das Medikament Gepotidacin von GSK vorrangig prüfen um festzustellen, ob es für die Behandlung unkomplizierter urogenitaler ......
10.08.25 - 11:48
 Proactive health highlights: GSK, Novo, Futura, Faron, Immupharma, Creo and more (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
08.08.25 - 23:00
 Drugmaker GSK lands £372m in Covid jab pact (DailyMail)
 
The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19....
08.08.25 - 13:12
 GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.08.25 - 10:12
 GSK wins settlement, future royalties in CureVac mRNA patent dispute (Alliance)
 
GSK PLC on Friday said it will receive an upfront payment of $370 million from CureVac BV, following a patent settlement...
08.08.25 - 10:06
 Biontech und Curevac: Streit um mRNA-Impfstoffe – GSK kassiert 500 Millionen Dollar (Handelsblatt)
 
In einem Patentstreit um Corona-Impfstoffe zwischen Curevac, Pfizer und Biontech wurde nun ein Vergleich geschlossen. Profitieren soll dabei auch der britische Arzneiriese GSK....
08.08.25 - 09:36
 GSK Set for $500 Million Payment From mRNA Lawsuit Settlement (Bloomberg)
 
CureVac NV has settled a long-running patent dispute over mRNA vaccines with Pfizer Inc. and BioNTech SE in the US, which will see CureVac's former collaborator GSK Plc receive as much as $500 million and 1% of royalties from future vaccine sales....
08.08.25 - 09:12
 GSK To Get $370 Mln Upfront Payment From CureVac With MRNA Patent Settlement (AFX)
 
LONDON (dpa-AFX) - British drug major GSK plc (GSK, GSK.L) announced Friday that it will receive an upfront settlement of $370 million from CureVac N.V. following the mRNA patent settlement reache......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Nur übereilt bestimmt die Neigung sich. - Johann Wolfgang von Goethe
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!